NNKTT120, an anti-iNKT cell monoclonal antibody, produces rapid and sustained iNKT cell depletion in adults with sickle cell disease

Authors

Joshua J. Field, Medical College of Wisconsin
Elaine Majerus, Washington University School of Medicine in St. Louis
Kenneth I. Ataga, University of North Carolina at Chapel Hill
Elliot P. Vichinsky, Oakland Childrens's Hospital
Robert Schaub, NKT Therapeutics, Waltham
Robert Mashal, NKT Therapeutics, Waltham
David G. Nathan, Harvard University

Journal

PLoS One

Publication Date

2017

Volume

12

Issue

2

Inclusive Pages

e0171067

Document Type

Open Access Publication

DOI

10.1371/journal.pone.0171067

Rights and Permissions

Field JJ, Majerus E, Ataga KI, Vichinsky EP, Schaub R, et al. (2017) NNKTT120, an anti-iNKT cell monoclonal antibody, produces rapid and sustained iNKT cell depletion in adults with sickle cell disease. PLOS ONE 12(2): e0171067. https://doi.org/10.1371/journal.pone.0171067

Recommended Citation

Field, Joshua J.; Majerus, Elaine; Ataga, Kenneth I.; Vichinsky, Elliot P.; Schaub, Robert; Mashal, Robert; and Nathan, David G., "NNKTT120, an anti-iNKT cell monoclonal antibody, produces rapid and sustained iNKT cell depletion in adults with sickle cell disease." PLoS One. 12, 2. e0171067. (2017).
https://digitalcommons.wustl.edu/open_access_pubs/5831